Gunaldi Meral, Goksu Sema, Erdem Dilek, Gunduz Seyda, Okuturlar Yildiz, Tiken Eda, Kahraman Sibel, Inan Yesim Ozdem, Genc Tugrul Burak, Yildirim Mustafa
Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital Istanbul, Turkey.
Department of Medical Oncology, Kayseri Research and Training Hospital Kayseri, Turkey.
Int J Clin Exp Med. 2015 Apr 15;8(4):5937-42. eCollection 2015.
Increasing amounts of evidence suggest patient-related systemic inflammatory response (SIR) as a powerful prognostic factor in cancer and applicability of SIR as a prognostic factor has been investigated.
To evaluate the prognostic significance of SIR, which is among routinely analysed blood parameters in patients with all stages of gastric cancer (GC).
A total of 245 patients with gastric cancer who were followed up and treated in four clinics of medical oncology were included in the study. At first admission of the patients, from routinely determined whole blood cell counts in medical oncology clinics, their neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) values were estimated and recorded before initiating chemo- or radiotherapy. A univariate non-parametric analytical method and chi-square test examined the correlation between prognostic factors, and survival rates. Survival curves were estimated using the Kaplan-Meier method.
Sixty-eight (27.8%) female and 177 (72.2) male patients (total n=245) were included in the study. When NLR was used as an indicator of SIR, 108 (44.1%) patients were SIR negative and 137 (55.9%) patients were SIR positive. When PLR was used as an indicator of SIR, SIR negativity and positivity were detected in 93(38%) and 152 (62%) patients, respectively. A statistically significant correlation was found between status of lymph node metastasis, stage of the disease and NLR (P=0.001, P=0.017). SIR determined with PLR was found to be correlated with the depth of tumor invasion and stage of the disease (P=0.016, P=0.033). A significant correlation was not detected between PLR and survival (P=0.405).
According to our study, parameters of NLR and PLR calculated preoperatively from peripheral blood samples can be used in patients with various sizes of tumours in different disease stages. Still based on our results, NLR calculated during diagnostic workup is a parameter with a prognostic value. In addition, NLR is a determinative factor in the selection of surgical method and chemotherapeutic modalities, which also functions as a potential contributory marker in effective immunotherapeutic strategies.
越来越多的证据表明,与患者相关的全身炎症反应(SIR)是癌症中一个强大的预后因素,并且已经对SIR作为预后因素的适用性进行了研究。
评估SIR的预后意义,SIR是各期胃癌(GC)患者常规分析的血液参数之一。
本研究纳入了在四个肿瘤内科诊所接受随访和治疗的245例胃癌患者。在患者首次入院时,根据肿瘤内科诊所常规测定的全血细胞计数,在开始化疗或放疗前估算并记录他们的中性粒细胞/淋巴细胞比值(NLR)和血小板/淋巴细胞比值(PLR)。采用单变量非参数分析方法和卡方检验来检验预后因素与生存率之间的相关性。使用Kaplan-Meier方法估计生存曲线。
本研究纳入了68例(27.8%)女性和177例(72.2%)男性患者(共245例)。当使用NLR作为SIR的指标时,108例(44.1%)患者SIR为阴性,137例(55.9%)患者SIR为阳性。当使用PLR作为SIR的指标时,分别在93例(38%)和152例(62%)患者中检测到SIR阴性和阳性。发现淋巴结转移状态、疾病分期与NLR之间存在统计学显著相关性(P=0.001,P=0.017)。发现用PLR确定的SIR与肿瘤浸润深度和疾病分期相关(P=0.016,P=0.033)。未检测到PLR与生存率之间存在显著相关性(P=0.405)。
根据我们的研究,术前从外周血样本计算的NLR和PLR参数可用于不同疾病阶段各种大小肿瘤的患者。仍然基于我们的结果,诊断检查期间计算的NLR是一个具有预后价值的参数。此外,NLR是手术方法和化疗方式选择的决定性因素,在有效的免疫治疗策略中也作为一个潜在的辅助标志物发挥作用。